Free Trial

PowerUp Acquisition (PWUP) Competitors

PowerUp Acquisition logo
$11.50 0.00 (0.00%)
(As of 11/20/2024 ET)

PWUP vs. CTNM, AMLX, ALEC, QTTB, KMDA, BTMD, DSGN, CYRX, ACIU, and JSPR

Should you be buying PowerUp Acquisition stock or one of its competitors? The main competitors of PowerUp Acquisition include Contineum Therapeutics (CTNM), Amylyx Pharmaceuticals (AMLX), Alector (ALEC), Q32 Bio (QTTB), Kamada (KMDA), biote (BTMD), Design Therapeutics (DSGN), Cryoport (CYRX), AC Immune (ACIU), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry.

PowerUp Acquisition vs.

Contineum Therapeutics (NASDAQ:CTNM) and PowerUp Acquisition (NASDAQ:PWUP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.

19.2% of PowerUp Acquisition shares are owned by institutional investors. 48.0% of PowerUp Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Contineum Therapeutics has higher revenue and earnings than PowerUp Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Contineum Therapeutics$50M7.04$22.72MN/AN/A
PowerUp AcquisitionN/AN/AN/AN/AN/A

Contineum Therapeutics presently has a consensus target price of $29.25, suggesting a potential upside of 114.13%. Given Contineum Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Contineum Therapeutics is more favorable than PowerUp Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Contineum Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
PowerUp Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Contineum Therapeutics received 7 more outperform votes than PowerUp Acquisition when rated by MarketBeat users.

CompanyUnderperformOutperform
Contineum TherapeuticsOutperform Votes
7
100.00%
Underperform Votes
No Votes
PowerUp AcquisitionN/AN/A

PowerUp Acquisition's return on equity of 0.00% beat Contineum Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Contineum TherapeuticsN/A -49.92% -20.52%
PowerUp Acquisition N/A N/A N/A

In the previous week, Contineum Therapeutics had 2 more articles in the media than PowerUp Acquisition. MarketBeat recorded 2 mentions for Contineum Therapeutics and 0 mentions for PowerUp Acquisition. Contineum Therapeutics' average media sentiment score of 0.03 beat PowerUp Acquisition's score of 0.00 indicating that Contineum Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Contineum Therapeutics Neutral
PowerUp Acquisition Neutral

Summary

Contineum Therapeutics beats PowerUp Acquisition on 8 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PWUP vs. The Competition

MetricPowerUp AcquisitionHolding Offices IndustryUnclassified SectorNASDAQ Exchange
Market Cap$89.36M$261.73M$108.28M$8.80B
Dividend YieldN/A7.57%5.20%4.07%
P/E RatioN/A2.161.0713.60
Price / SalesN/A155.741.1687.40
Price / CashN/A80.91100.1736.27
Price / BookN/A73.36519.866.33
Net IncomeN/A$32.24M$2.82M$225.93M
7 Day Performance-0.80%-0.40%-0.41%-0.96%
1 Month Performance-11.54%-4.95%-3.37%1.06%
1 Year Performance5.80%14.10%15.45%26.59%

PowerUp Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PWUP
PowerUp Acquisition
N/A$11.50
flat
N/AN/A$89.36MN/A0.00N/A
CTNM
Contineum Therapeutics
1.6433 of 5 stars
$13.66
+0.1%
$29.25
+114.1%
N/A$352.16M$50M0.0031
AMLX
Amylyx Pharmaceuticals
4.3626 of 5 stars
$5.09
-2.7%
$11.43
+124.5%
-59.5%$348.92M$380.79M0.00200Analyst Upgrade
ALEC
Alector
4.3736 of 5 stars
$3.54
-2.5%
$20.67
+483.8%
-26.1%$346.67M$97.06M-2.14270Positive News
QTTB
Q32 Bio
1.6142 of 5 stars
$28.00
+2.6%
$72.33
+158.3%
N/A$341.04M$1.16M0.0039
KMDA
Kamada
3.8063 of 5 stars
$5.83
+0.2%
$14.50
+148.7%
+23.3%$335.11M$142.52M20.79360Analyst Revision
BTMD
biote
3.1975 of 5 stars
$5.97
-1.5%
$8.39
+40.5%
+19.8%$323.69M$185.36M23.31194
DSGN
Design Therapeutics
1.7541 of 5 stars
$5.66
+3.3%
$7.00
+23.7%
+145.7%$320.47MN/A0.0040
CYRX
Cryoport
2.8991 of 5 stars
$6.46
-1.7%
$12.50
+93.5%
-52.6%$319.32M$233.26M-1.941,170Insider Trade
ACIU
AC Immune
2.3118 of 5 stars
$3.22
-0.6%
$12.00
+272.7%
+0.0%$318.59M$16.48M0.00140Positive News
JSPR
Jasper Therapeutics
2.6633 of 5 stars
$21.18
+1.0%
$74.86
+253.4%
+227.3%$317.70MN/A0.0020

Related Companies and Tools


This page (NASDAQ:PWUP) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners